Hyperuricemia treatment in acute heart failure patients does
not improve their long-term prognosis: A propensity score
matched analysis from the AHEAD registry

J 2019

Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry

MIKLÍKOVÁ, Marie; Jiří JARKOVSKÝ; Klára BENEŠOVÁ; Jiří VÍTOVEC; Ales LINHART et al.

Základní údaje

Originální název

Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry

Autoři

Vydání

Clinical Cardiology, Hoboken, John Wiley and Sons Inc. 2019, 0160-9289

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.248

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/19:00110765

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1002/clc.23197

UT WoS

000478082600003

EID Scopus

2-s2.0-85066830350

Klíčová slova anglicky

acute heart failure; AHEAD; allopurinol

Štítky

14110115, 14110116, 14110211, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 24. 9. 2019 08:47, Mgr. Tereza Miškechová

Anotace

V originále

Background Hyperuricemia is associated with a poorer prognosis in heart failure (HF) patients. Benefits of hyperuricemia treatment with allopurinol have not yet been confirmed in clinical practice. The aim of our work was to assess the benefit of allopurinol treatment in a large cohort of HF patients. Methods The prospective acute heart failure registry (AHEAD) was used to select 3160 hospitalized patients with a known level of uric acid (UA) who were discharged in a stable condition. Hyperuricemia was defined as UA >= 500 mu moL/L and/or allopurinol treatment at admission. The patients were classified into three groups: without hyperuricemia, with treated hyperuricemia, and with untreated hyperuricemia at discharge. Two- and five-year all-cause mortality were defined as endpoints. Patients without hyperuricemia, unlike those with hyperuricemia, had a higher left ventricular ejection fraction, a better renal function, and higher hemoglobin levels, had less frequently diabetes mellitus and atrial fibrillation, and showed better tolerance to treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and/or beta-blockers. Results In a primary analysis, the patients without hyperuricemia had the highest survival rate. After using the propensity score to set up comparable groups, the patients without hyperuricemia had a similar 5-year survival rate as those with untreated hyperuricemia (42.0% vs 39.7%, P = 0.362) whereas those with treated hyperuricemia had a poorer prognosis (32.4% survival rate, P = 0.006 vs non-hyperuricemia group and P = 0.073 vs untreated group). Conclusion Hyperuricemia was associated with an unfavorable cardiovascular risk profile in HF patients. Treatment with low doses of allopurinol did not improve the prognosis of HF patients.

Návaznosti

MUNI/A/1250/2017, interní kód MU

Název: Validace Rule-out/rule-in protokolu u pacientů s bolestí na hrudi – pokračování v prospektivní studii

Investor: Masarykova univerzita, Validace Rule-out/rule-in protokolu u pacientů s bolestí na hrudi – pokračování v prospektivní studii, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

MIKLÍKOVÁ, Marie; Jiří JARKOVSKÝ; Klára BENEŠOVÁ; Jiří VÍTOVEC; Ales LINHART; Petr WIDIMSKY; Lenka ŠPINAROVÁ; Kamil ZEMAN; Jan BELOHLAVEK; Filip MALEK; Marián FELŠŐCI; Jiri KETTNER; Petr OSTADAL; Cestmir CIHALIK; Jiří ŠPÁC; Hikmet AL-HITI; Marian FEDORCO; Richard FOJT; Andreas KRUGER; Josef MALEK; Tereza MIKUSOVA; Zdenek MONHART; Stanislava BOHACOVA; Lidka POHLUDKOVA; Filip ROHAC; Jan VACLAVIK; Dagmar VONDRAKOVA; Klaudia VYSKOCILOVA; Miroslav BAMBUCH; Gabriela DOSTALOVA; Stepan HAVRANEK; Ivana SVOBODOVÁ; Ladislav DUŠEK; Jindřich ŠPINAR; Roman MIKLIK a Jiří PAŘENICA. Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry. Clinical Cardiology. Hoboken: John Wiley and Sons Inc., 2019, roč. 42, č. 8, s. 720-727. ISSN 0160-9289. Dostupné z: https://doi.org/10.1002/clc.23197.

@article{1561416,
   author = {Miklíková, Marie and Jarkovský, Jiří and Benešová, Klára and Vítovec, Jiří and Linhart, Ales and Widimsky, Petr and Špinarová, Lenka and Zeman, Kamil and Belohlavek, Jan and Malek, Filip and Felšőci, Marián and Kettner, Jiri and Ostadal, Petr and Cihalik, Cestmir and Špác, Jiří and AlandHiti, Hikmet and Fedorco, Marian and Fojt, Richard and Kruger, Andreas and Malek, Josef and Mikusova, Tereza and Monhart, Zdenek and Bohacova, Stanislava and Pohludkova, Lidka and Rohac, Filip and Vaclavik, Jan and Vondrakova, Dagmar and Vyskocilova, Klaudia and Bambuch, Miroslav and Dostalova, Gabriela and Havranek, Stepan and Svobodová, Ivana and Dušek, Ladislav and Špinar, Jindřich and Miklik, Roman and Pařenica, Jiří},
   article_location = {Hoboken},
   article_number = {8},
   doi = {https://doi.org/10.1002/clc.23197},
   keywords = {acute heart failure; AHEAD; allopurinol},
   language = {eng},
   issn = {0160-9289},
   journal = {Clinical Cardiology},
   title = {Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry},
   url = {http://dx.doi.org/10.1002/clc.23197},
   volume = {42},
   year = {2019}
}

TY  - JOUR
ID  - 1561416
AU  - Miklíková, Marie - Jarkovský, Jiří - Benešová, Klára - Vítovec, Jiří - Linhart, Ales - Widimsky, Petr - Špinarová, Lenka - Zeman, Kamil - Belohlavek, Jan - Malek, Filip - Felšőci, Marián - Kettner, Jiri - Ostadal, Petr - Cihalik, Cestmir - Špác, Jiří - Al-Hiti, Hikmet - Fedorco, Marian - Fojt, Richard - Kruger, Andreas - Malek, Josef - Mikusova, Tereza - Monhart, Zdenek - Bohacova, Stanislava - Pohludkova, Lidka - Rohac, Filip - Vaclavik, Jan - Vondrakova, Dagmar - Vyskocilova, Klaudia - Bambuch, Miroslav - Dostalova, Gabriela - Havranek, Stepan - Svobodová, Ivana - Dušek, Ladislav - Špinar, Jindřich - Miklik, Roman - Pařenica, Jiří
PY  - 2019
TI  - Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry
JF  - Clinical Cardiology
VL  - 42
IS  - 8
SP  - 720-727
EP  - 720-727
PB  - John Wiley and Sons Inc.
SN  - 01609289
KW  - acute heart failure
KW  - AHEAD
KW  - allopurinol
UR  - http://dx.doi.org/10.1002/clc.23197
L2  - http://dx.doi.org/10.1002/clc.23197
N2  - Background Hyperuricemia is associated with a poorer prognosis in heart failure (HF) patients. Benefits of hyperuricemia treatment with allopurinol have not yet been confirmed in clinical practice. The aim of our work was to assess the benefit of allopurinol treatment in a large cohort of HF patients. Methods The prospective acute heart failure registry (AHEAD) was used to select 3160 hospitalized patients with a known level of uric acid (UA) who were discharged in a stable condition. Hyperuricemia was defined as UA >= 500 mu moL/L and/or allopurinol treatment at admission. The patients were classified into three groups: without hyperuricemia, with treated hyperuricemia, and with untreated hyperuricemia at discharge. Two- and five-year all-cause mortality were defined as endpoints. Patients without hyperuricemia, unlike those with hyperuricemia, had a higher left ventricular ejection fraction, a better renal function, and higher hemoglobin levels, had less frequently diabetes mellitus and atrial fibrillation, and showed better tolerance to treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and/or beta-blockers. Results In a primary analysis, the patients without hyperuricemia had the highest survival rate. After using the propensity score to set up comparable groups, the patients without hyperuricemia had a similar 5-year survival rate as those with untreated hyperuricemia (42.0% vs 39.7%, P = 0.362) whereas those with treated hyperuricemia had a poorer prognosis (32.4% survival rate, P = 0.006 vs non-hyperuricemia group and P = 0.073 vs untreated group). Conclusion Hyperuricemia was associated with an unfavorable cardiovascular risk profile in HF patients. Treatment with low doses of allopurinol did not improve the prognosis of HF patients.
ER  -

MIKLÍKOVÁ, Marie; Jiří JARKOVSKÝ; Klára BENEŠOVÁ; Jiří VÍTOVEC; Ales LINHART; Petr WIDIMSKY; Lenka ŠPINAROVÁ; Kamil ZEMAN; Jan BELOHLAVEK; Filip MALEK; Marián FELŠ$\backslash$H OCI; Jiri KETTNER; Petr OSTADAL; Cestmir CIHALIK; Jiří ŠPÁC; Hikmet AL-HITI; Marian FEDORCO; Richard FOJT; Andreas KRUGER; Josef MALEK; Tereza MIKUSOVA; Zdenek MONHART; Stanislava BOHACOVA; Lidka POHLUDKOVA; Filip ROHAC; Jan VACLAVIK; Dagmar VONDRAKOVA; Klaudia VYSKOCILOVA; Miroslav BAMBUCH; Gabriela DOSTALOVA; Stepan HAVRANEK; Ivana SVOBODOVÁ; Ladislav DUŠEK; Jindřich ŠPINAR; Roman MIKLIK a Jiří PAŘENICA. Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry. \textit{Clinical Cardiology}. Hoboken: John Wiley and Sons Inc., 2019, roč.~42, č.~8, s.~720-727. ISSN~0160-9289. Dostupné z: https://doi.org/10.1002/clc.23197.

Přehled o publikaci